Congenital Cutis Laxa

Total Page:16

File Type:pdf, Size:1020Kb

Congenital Cutis Laxa Congenital Cutis Laxa Congenital cutis laxa is a rare inherited connective tissue iv. A broad flat nose disorder manifested by inelastic, loose, pendulous skin, giving v. Sagging cheeks the appearance of premature aging. vi. Long upper lip vii. Short columella GENETICS/BASIC DEFECTS viii. Large ears e. Skin 1. Genetic heterogeneity i. Prominent skin folds (loose skin) around the a. Autosomal recessive cutis laxa: the most common knees, abdomen, and thighs type ii. No hyperelasticity, fragility, or difficulty in wound i. Type I autosomal recessive cutis laxa: less fre- healing quent than type II f. Skeletal muscular abnormalities ii. Type II autosomal recessive cutis laxa i. Dislocation of the hips b. Autosomal dominant cutis laxa ii. Joint hyperextensibility c. X-liked recessive cutis laxa iii. Hernia i. Previously called occipital horn syndrome iv. Osteoporosis ii. At present, best termed as Ehlers-Danlos syn- g. Cardiopulmonary abnormalities drome type IX i. Severe pulmonary emphysema resulting from 2. Biochemical and molecular defects generalized elastolysis a. Autosomal recessive cutis laxa type I: molecular studies a) Tachypnea in a large consanguineous Turkish family demon- b) Pneumonitis strated the presence of a homozygous missense muta- c) Airway obstruction tion (T998C) in the fibulin-5 (FBLN5) gene, resulting d) Severe hypoxia in a serine-to-proline (S227P) substitution in the e) Respiratory failure fourth calcium-binding epidermal growth factor-like ii. Cardiac abnormalities domain of fibulin-5 protein a) Right ventricular enlargement b. Autosomal dominant cutis laxa b) Cor pulmonale i. Can be caused by mutations in the elastin gene c) Bundle branch block ii. Molecular heterogeneity cannot be excluded d) Pulmonary artery hypoplasia and stenosis c. X-linked recessive cutis laxa e) Dilated and tortuous carotid, vertebral, and i. Caused by mutations in the ATP7A gene pulmonary arteries ii. Characterized by diminished activity of lysyl f) Aortic aneurysm oxidase in the skin from affected males h. Other abnormalities iii. Reduced serum copper and ceruloplasmin in i. Hernias affected males, suggesting that the lysyl oxidase a) Inguinal deficiency may be secondary to a defect in copper b) Diaphragmatic metabolism c) Ventral iv. Now known to be allelic to Menkes disease d) Inguinal ii. Hollow viscus (pharynx, esophagus, and rectum) CLINICAL FEATURES diverticula 1. Autosomal recessive cutis laxa iii. Oral abnormalities a. More common than the autosomal dominant form a) Deep and resonant voice secondary to lax b. Autosomal recessive cutis laxa type I vocal cords i. The poorest prognosis b) Loose oral and pharyngeal mucosa ii. Pulmonary emphysema iv. Genitourinary abnormalities iii. Umbilical and inguinal hernias a) Bladder diverticula iv. Gastrointestinal and vesicourinary tract diverticuli b) Vaginal prolapse c. Autosomal recessive cutis laxa type II, also called v. Dental caries cutis laxa with joint laxity and developmental delay i. A shorter life span d. Characteristic facies 2. Autosomal dominant cutis laxa i. Appearing aged due to accentuation of skin folds a. A relatively benign disorder and less common than ii. Downward slanting palpebral fissures the autosomal recessive form iii. Blepharochalasis and, at times, ectropion, adding b. Cutaneous laxity to the aged appearance c. Clinical features presenting in infancy 207 208 CONGENITAL CUTIS LAXA i. Intrauterine growth retardation iii. Poor skin elasticity in affected areas ii. Delayed fontanelle closure iv. Increased palmar and plantar creases iii. Ligamental laxity v. A prominent venous pattern on the chest iv. Episodes of edema may precede the skin vi. Mental retardation changes, usually within the first 2 months of life vii. Microcephaly v. Aging appearance by the end of the second year viii. Hypotonia vi. Pulmonary emphysema common due to a loss of ix. Musculoskeletal abnormalities elastic tissue in the lungs b. De Barsey syndrome d. Skin changes presenting in adulthood i. Cutis laxa (wrinkled atrophic skin) i. Usually no internal defects ii. Retarded psychomotor development ii. Having a normal life expectancy iii. Corneal clouding due to degeneration of the e. Aging appearance tunica elastica of the cornea i. Drooping of eyelids iv. Intrauterine growth retardation ii. Sagging facial skin v. Pseudoathetoid movement iii. Accentuation of the nasolabial and other facial vi. Muscular hypotonia folds vii. Hypermobility of small joints iv. Often hooked nose with everted nostrils c. Costello syndrome v. Long philtrum i. Nasal papillomata f. Few complications ii. Coarse facies i. Hoarseness iii. Mental retardation ii. Pulmonary artery stenosis iv. Growth retardation iii. Mitral valve prolapse v. Cutis laxa iv. Hernia d. SCARF syndrome v. Bronchiectasis i. An X-linked recessive disorder vi. Joint dislocations ii. Skeletal abnormalities vii. Tortuosity and dilatation of carotid arteries and a) Craniostenosis aorta b) Enamel hypoplasia, hypocalcification of the viii. Dilatation of sinuses of Valsalva teeth ix. Coarctation of the aorta c) Short sternum g. Normal life span d) Pectus carinatum 3. X-linked recessive cutis laxa e) Abnormally shaped vertebrae a. Long and thin face, neck, and trunk f) Abnormal modeling of long tubular bones b. Mild hyperelastic (but not lax) and bruisable skin iii. Cutaneous abnormalities with resultant atrophic scars a) Cutis laxa c. Musculoskeletal abnormalities b) Wide-spaced nipples i. Inferior cranial spurs (occipital horns) c) Diastasis recti a) A constant feature d) Umbilical hernia b) May be palpated iv. Ambiguous genitalia c) May become larger with age a) Micropenis d) May represent ectopic bone formation within b) Perineal hypospadias the trapezius and sternocleidomastoid aponeur- v. Retardation: mild to moderate psychomotor oses retardation ii. Skeletal dysplasia most prominent at the wrists vi. Facial abnormalities and elbows a) Multiple hairwhorls iii. Limitation of extension of the elbows, shoulders, b) Epicanthal folds knees c) Ptosis iv. Hypermobility of the finger joints d) High and broad nasal root v. Pes planus e) Low-set and posteriorly rotated ears vi. Genu valga f) Small chin vii. Pectus excavatum or carinatum (40%) d. Obstructive uropathy secondary to bladder diverticula with bladder neck obstruction (60–70%) DIAGNOSTIC INVESTIGATIONS e. Various hernias (hiatal, femoral, and inguinal) (35%) 1. Radiography f. Chronic diarrhea (40%) a. Autosomal recessive cutis laxa 4. Differential diagnosis i. Presence of a variety of hernias a. Wrinkling skin syndrome a) Femoral i. A rare autosomal recessive disorder of the con- b) Inguinal nective tissue c) Obturator ii. Wrinkled skin over abdomen and on the dorsum d) Hiatal of the hands and feet ii. Eventrations of the diaphragm CONGENITAL CUTIS LAXA 209 iii. Rectal and uterine prolapse iii. Mutation scanning: heteroduplex analysis, avail- iv. Common intrathoracic abnormalities able on a clinical basis, to detect small mutations a) Hyperexpansion of the lungs b) Emphysema which may lead to cor pul- GENETIC COUNSELING monale and death in childhood c) Upper airway obstruction caused by exces- 1. Recurrence risk sively lax vocal cords, leading to congestive a. Patient’s sib heart failure i. Autosomal recessive cutis laxa: 25% d) Frequent peripheral pulmonary artery steno- ii. Autosomal dominant cutis laxa: not increased sis and aortic dilatation unless a parent is affected v. Diverticula involving the entire bowel but no iii. X-linked recessive cutis laxa: functional significance a) When the mother is a carrier: 50% risk of vi. Diverticula of the urinary tract predisposing to brother will be affected and 50% of sisters infection or causing obstruction carriers vii. Arteriographic changes b) When mother is not a carrier: the recurrence a) Peripheral pulmonary stenosis risk is low but greater than that for the gen- b) Dilatation and tortuosity of the aorta eral population because the risk of germline c) A peculiar corkscrew appearance of the mosaicism in mother is not known peripheral systemic arteries, similar to the b. Patient’s offspring arterial changes seen in Menkes syndrome i. Autosomal recessive cutis laxa: not increased b. X-linked recessive cutis laxa unless the spouse is a carrier or affected i. Occipital exostosis (horns) symmetrically located ii. Autosomal dominant cutis laxa: 50% on each side of the foramen magnum iii. X-linked recessive cutis laxa: Males with occip- ii. Short clavicles with a widened medullary cavity ital horn syndrome will pass the disease-causing iii. Hammer-shaped distal extremities gene to all of their daughters and none of their iv. Focal hyperostosis of the femora at sites of ten- sons don and ligament insertion 2. Prenatal diagnosis v. Carpal fusion involving capitate-hamate and a. DNA-based analysis on fetal DNA obtained from trapezium-trapezoid coalescence (over 50%) amniocentesis or CVS for the previously character- vi. Deformation of humerus, radius, ulna, tibia, ized disease-causing mutation fibula (90%) b. Fetal sex determination for X-linked recessive cutis vii. Osteoporosis (70%) laxa (occipital horn syndrome) viii. Narrowing of rib cage (65%) 3. Management ix. Dislocation of radial head (40%) a. Supportive therapy: antibiotic prophylaxis for bladder x. Mild platyspondyly infection xi. Coxa valga b. Surgery for bladder diverticula xii. Flattening of acetabular rooofs c. Plastic surgery to improve aging appearance 2. Histopathological abnormality: fragmentation and i. Serial excisions of the skin paucity of elastic fibers in the skin ii. Blepharoplasty
Recommended publications
  • Mackenzie's Mission Gene & Condition List
    Mackenzie’s Mission Gene & Condition List What conditions are being screened for in Mackenzie’s Mission? Genetic carrier screening offered through this research study has been carefully developed. It is focused on providing people with information about their chance of having children with a severe genetic condition occurring in childhood. The screening is designed to provide genetic information that is relevant and useful, and to minimise uncertain and unclear information. How the conditions and genes are selected The Mackenzie’s Mission reproductive genetic carrier screen currently includes approximately 1300 genes which are associated with about 750 conditions. The reason there are fewer conditions than genes is that some genetic conditions can be caused by changes in more than one gene. The gene list is reviewed regularly. To select the conditions and genes to be screened, a committee comprised of experts in genetics and screening was established including: clinical geneticists, genetic scientists, a genetic pathologist, genetic counsellors, an ethicist and a parent of a child with a genetic condition. The following criteria were developed and are used to select the genes to be included: • Screening the gene is technically possible using currently available technology • The gene is known to cause a genetic condition • The condition affects people in childhood • The condition has a serious impact on a person’s quality of life and/or is life-limiting o For many of the conditions there is no treatment or the treatment is very burdensome for the child and their family. For some conditions very early diagnosis and treatment can make a difference for the child.
    [Show full text]
  • Centometabolic® COMBINING GENETIC and BIOCHEMICAL TESTING for the FAST and COMPREHENSIVE DIAGNOSTIC of METABOLIC DISORDERS
    CentoMetabolic® COMBINING GENETIC AND BIOCHEMICAL TESTING FOR THE FAST AND COMPREHENSIVE DIAGNOSTIC OF METABOLIC DISORDERS GENE ASSOCIATED DISEASE(S) ABCA1 HDL deficiency, familial, 1; Tangier disease ABCB4 Cholestasis, progressive familial intrahepatic 3 ABCC2 Dubin-Johnson syndrome ABCD1 Adrenoleukodystrophy; Adrenomyeloneuropathy, adult ABCD4 Methylmalonic aciduria and homocystinuria, cblJ type ABCG5 Sitosterolemia 2 ABCG8 Sitosterolemia 1 ACAT1 Alpha-methylacetoacetic aciduria ADA Adenosine deaminase deficiency AGA Aspartylglucosaminuria AGL Glycogen storage disease IIIa; Glycogen storage disease IIIb AGPS Rhizomelic chondrodysplasia punctata, type 3 AGXT Hyperoxaluria, primary, type 1 ALAD Porphyria, acute hepatic ALAS2 Anemia, sideroblastic, 1; Protoporphyria, erythropoietic, X-linked ALDH4A1 Hyperprolinemia, type II ALDOA Glycogen storage disease XII ALDOB Fructose intolerance, hereditary ALG3 Congenital disorder of glycosylation, type Id ALPL Hypophosphatasia, adult; Hypophosphatasia, childhood; Hypophosphatasia, infantile; Odontohypophosphatasia ANTXR2 Hyaline fibromatosis syndrome APOA2 Hypercholesterolemia, familial, modifier of APOA5 Hyperchylomicronemia, late-onset APOB Hypercholesterolemia, familial, 2 APOC2 Hyperlipoproteinemia, type Ib APOE Sea-blue histiocyte disease; Hyperlipoproteinemia, type III ARG1 Argininemia ARSA Metachromatic leukodystrophy ARSB Mucopolysaccharidosis type VI (Maroteaux-Lamy) 1 GENE ASSOCIATED DISEASE(S) ASAH1 Farber lipogranulomatosis; Spinal muscular atrophy with progressive myoclonic epilepsy
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0210567 A1 Bevec (43) Pub
    US 2010O2.10567A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0210567 A1 Bevec (43) Pub. Date: Aug. 19, 2010 (54) USE OF ATUFTSINASATHERAPEUTIC Publication Classification AGENT (51) Int. Cl. A638/07 (2006.01) (76) Inventor: Dorian Bevec, Germering (DE) C07K 5/103 (2006.01) A6IP35/00 (2006.01) Correspondence Address: A6IPL/I6 (2006.01) WINSTEAD PC A6IP3L/20 (2006.01) i. 2O1 US (52) U.S. Cl. ........................................... 514/18: 530/330 9 (US) (57) ABSTRACT (21) Appl. No.: 12/677,311 The present invention is directed to the use of the peptide compound Thr-Lys-Pro-Arg-OH as a therapeutic agent for (22) PCT Filed: Sep. 9, 2008 the prophylaxis and/or treatment of cancer, autoimmune dis eases, fibrotic diseases, inflammatory diseases, neurodegen (86). PCT No.: PCT/EP2008/007470 erative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the S371 (c)(1), present invention relates to pharmaceutical compositions (2), (4) Date: Mar. 10, 2010 preferably inform of a lyophilisate or liquid buffersolution or artificial mother milk formulation or mother milk substitute (30) Foreign Application Priority Data containing the peptide Thr-Lys-Pro-Arg-OH optionally together with at least one pharmaceutically acceptable car Sep. 11, 2007 (EP) .................................. O7017754.8 rier, cryoprotectant, lyoprotectant, excipient and/or diluent. US 2010/0210567 A1 Aug. 19, 2010 USE OF ATUFTSNASATHERAPEUTIC ment of Hepatitis BVirus infection, diseases caused by Hepa AGENT titis B Virus infection, acute hepatitis, chronic hepatitis, full minant liver failure, liver cirrhosis, cancer associated with Hepatitis B Virus infection. 0001. The present invention is directed to the use of the Cancer, Tumors, Proliferative Diseases, Malignancies and peptide compound Thr-Lys-Pro-Arg-OH (Tuftsin) as a thera their Metastases peutic agent for the prophylaxis and/or treatment of cancer, 0008.
    [Show full text]
  • With a Learning Disability; Guidance for General Practice
    Improving identification of people with a learning disability: guidance for general practice NHS England and Improvement Publishing Approval Reference: 001030 Version 1 NHS England and NHS Improvement Contents Introduction .................................................................................... 2 Actions for practices ....................................................................... 4 Appendix 1: List of codes that indicate a learning disability ........... 7 Appendix 2: List of codes that may indicate a learning disability . 14 Appendix 3: List of outdated codes .............................................. 20 Appendix 4: Learning disability identification check-list ............... 22 1 | Contents Introduction 1. The NHS Long Term Plan1 commits to improve uptake of the existing annual health check in primary care for people aged over 14 years with a learning disability, so that at least 75% of those eligible have a learning disability health check each year. 2. There is also a need to increase the number of people receiving the annual seasonal flu vaccination, given the level of avoidable mortality associated with respiratory problems. 3. In 2017/18, only 44.6% of patients with a learning disability received a flu vaccination and only 55.1% of patients with a learning disability received an annual learning disability health check.2 4. In June 2019, NHS England and NHS Improvement announced a series of measures to improve coverage of annual health checks and flu vaccination for people with a learning disability. One of the commitments was to improve the quality of registers for people with a learning disability3. Clinical coding review 5. Most GP practices have developed a register of their patients known to have a learning disability. This has been developed from clinical diagnoses, from information gathered from learning disabilities teams and social services and has formed the basis of registers for people with learning disability developed for the Quality and Outcomes Framework (QOF).
    [Show full text]
  • Pili Torti: a Feature of Numerous Congenital and Acquired Conditions
    Journal of Clinical Medicine Review Pili Torti: A Feature of Numerous Congenital and Acquired Conditions Aleksandra Hoffmann 1 , Anna Wa´skiel-Burnat 1,*, Jakub Z˙ ółkiewicz 1 , Leszek Blicharz 1, Adriana Rakowska 1, Mohamad Goldust 2 , Małgorzata Olszewska 1 and Lidia Rudnicka 1 1 Department of Dermatology, Medical University of Warsaw, Koszykowa 82A, 02-008 Warsaw, Poland; [email protected] (A.H.); [email protected] (J.Z.);˙ [email protected] (L.B.); [email protected] (A.R.); [email protected] (M.O.); [email protected] (L.R.) 2 Department of Dermatology, University Medical Center of the Johannes Gutenberg University, 55122 Mainz, Germany; [email protected] * Correspondence: [email protected]; Tel.: +48-22-5021-324; Fax: +48-22-824-2200 Abstract: Pili torti is a rare condition characterized by the presence of the hair shaft, which is flattened at irregular intervals and twisted 180◦ along its long axis. It is a form of hair shaft disorder with increased fragility. The condition is classified into inherited and acquired. Inherited forms may be either isolated or associated with numerous genetic diseases or syndromes (e.g., Menkes disease, Björnstad syndrome, Netherton syndrome, and Bazex-Dupré-Christol syndrome). Moreover, pili torti may be a feature of various ectodermal dysplasias (such as Rapp-Hodgkin syndrome and Ankyloblepharon-ectodermal defects-cleft lip/palate syndrome). Acquired pili torti was described in numerous forms of alopecia (e.g., lichen planopilaris, discoid lupus erythematosus, dissecting Citation: Hoffmann, A.; cellulitis, folliculitis decalvans, alopecia areata) as well as neoplastic and systemic diseases (such Wa´skiel-Burnat,A.; Zółkiewicz,˙ J.; as cutaneous T-cell lymphoma, scalp metastasis of breast cancer, anorexia nervosa, malnutrition, Blicharz, L.; Rakowska, A.; Goldust, M.; Olszewska, M.; Rudnicka, L.
    [Show full text]
  • Avero® Exon Global 280+ Genes
    Avero® Exon Global 280+ genes CARRIER DETECTION RESIDUAL GENE DISORDER NAME ETHNICITY FREQUENCY RATE RISK ABCB11 Progressive familial intrahepatic cholestasis, type II General Population 1 in 158 99% 1 in 15701 ABCC8 Familial hyperinsulinism, ABCC8-related General Population 1 in 112 99% 1 in 11101 Ashkenazi Jewish 1 in 52 99% 1 in 5101 Finnish 1 in 29 99% 1 in 2801 ABCD1 Adrenoleukodystrophy, X-linked General Population 1 in 10500 99% 1 in 1049901 Sephardic Jewish 1 in 10500 99% 1 in 1049901 ACAD9 Riboflavin responsive complex 1 deficiency (acyl-coenzyme General Population <1 in 500 99% 1 in 49901 dehydrogenase 9 deficiency) ACADM Medium-chain acyl-CoA dehydrogenase deficiency General Population 1 in 35 99% 1 in 3401 Asian 1 in 178 99% 1 in 17701 Caucasian 1 in 64 99% 1 in 6300 ACADVL Very long-chain acyl-CoA dehydrogenase deficiency General Population 1 in 86 99% 1 in 8500 Asian 1 in 194 99% 1 in 19301 Caucasian 1 in 88 99% 1 in 8700 ACAT1 Beta-ketothiolase deficiency General Population 1 in 347 99% 1 in 34601 Asian 1 in 289 99% 1 in 28801 Caucasian 1 in 354 99% 1 in 35301 ACOX1 Acyl-CoA oxidase I deficiency General Population <1 in 500 99% 1 in 49901 ACSF3 Combined malonic and methylmalonic aciduria General Population 1 in 86 99% 1 in 8500 ADA Adenosine deaminase deficiency General Population 1 in 224 99% 1 in 22301 ADAMTS2 Ehlers-Danlos syndrome, type VIIC General Population <1 in 500 99% 1 in 49901 Ashkenazi Jewish 1 in 248 99% 1 in 24701 6221 Riverside Drive, Suite 119, Irving, TX 75039 I Tel 877.232.9924 I averodx.com ©2020 Avero Diagnostics.
    [Show full text]
  • Molecular Genetics and Metabolism Reports 24 (2020) 100625
    Molecular Genetics and Metabolism Reports 24 (2020) 100625 Contents lists available at ScienceDirect Molecular Genetics and Metabolism Reports journal homepage: www.elsevier.com/locate/ymgmr Targeted next generation sequencing for newborn screening of Menkes T disease ⁎ Richard B. Parada,1, Stephen G. Kalerb,e, ,1, Evan Maucelic, Tanya Sokolskyc,d, Ling Yib, Arindam Bhattacharjeec,d a Department of Pediatric Newborn Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, United States of America b Section on Translational Neuroscience, Molecular Medicine Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, United States of America c Parabase Genomics, Inc., Boston, MA, United States of America d Baebies, Inc., Durham, NC, United States of America e Center for Gene Therapy, Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH, United States of America ARTICLE INFO ABSTRACT Keywords: Purpose: Population-based newborn screening (NBS) allows early detection and treatment of inherited disorders. Menkes disease For certain medically-actionable conditions, however, NBS is limited by the absence of reliable biochemical ATP7A signatures amenable to detection by current platforms. We sought to assess the analytic validity of an ATP7A Molecular genetics targeted next generation DNA sequencing assay as a potential newborn screen for one such disorder, Menkes Targeted next generation sequencing disease. Dried blood spots Methods: Dried blood spots from control or Menkes disease subjects (n = 22) were blindly analyzed for pa- Newborn screening thogenic variants in the copper transport gene, ATP7A. The analytical method was optimized to minimize cost and provide rapid turnaround time. Results: The algorithm correctly identified pathogenic ATP7A variants, including missense, nonsense, small insertions/deletions, and large copy number variants, in 21/22 (95.5%) of subjects, one of whom had incon- clusive diagnostic sequencing previously.
    [Show full text]
  • WO 2015/048577 A2 April 2015 (02.04.2015) W P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/048577 A2 April 2015 (02.04.2015) W P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 48/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/US20 14/057905 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 26 September 2014 (26.09.2014) KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (25) Filing Language: English PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (26) Publication Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/883,925 27 September 2013 (27.09.2013) US (84) Designated States (unless otherwise indicated, for every 61/898,043 31 October 2013 (3 1. 10.2013) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: EDITAS MEDICINE, INC.
    [Show full text]
  • Metabolic Cutis Laxa Syndromes
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Springer - Publisher Connector J Inherit Metab Dis (2011) 34:907–916 DOI 10.1007/s10545-011-9305-9 CDG - AN UPDATE Metabolic cutis laxa syndromes Miski Mohamed & Dorus Kouwenberg & Thatjana Gardeitchik & Uwe Kornak & Ron A. Wevers & Eva Morava Received: 28 October 2010 /Revised: 11 February 2011 /Accepted: 17 February 2011 /Published online: 23 March 2011 # The Author(s) 2011. This article is published with open access at Springerlink.com Abstract Cutis laxa is a rare skin disorder characterized by Disorders of Glycosylation (CDG). Since then several wrinkled, redundant, inelastic and sagging skin due to inborn errors of metabolism with cutis laxa have been defective synthesis of elastic fibers and other proteins of the described with variable severity. These include P5CS, extracellular matrix. Wrinkled, inelastic skin occurs in ATP6V0A2-CDG and PYCR1 defects. In spite of the many cases as an acquired condition. Syndromic forms of evolving number of cutis laxa-related diseases a large part cutis laxa, however, are caused by diverse genetic defects, of the cases remain genetically unsolved. In metabolic cutis mostly coding for structural extracellular matrix proteins. laxa syndromes the clinical and laboratory features might Surprisingly a number of metabolic disorders have been partially overlap, however there are some distinct, discrim- also found to be associated with inherited cutis laxa. inative features. In this review on metabolic diseases Menkes disease was the first metabolic disease reported causing cutis laxa we offer a practical approach for the with old-looking, wrinkled skin.
    [Show full text]
  • Discriminative Features in Three Autosomal Recessive Cutis Laxa Syndromes: Cutis Laxa IIA, Cutis Laxa IIB, and Geroderma Osteoplastica
    International Journal of Molecular Sciences Review Discriminative Features in Three Autosomal Recessive Cutis Laxa Syndromes: Cutis Laxa IIA, Cutis Laxa IIB, and Geroderma Osteoplastica Ariana Kariminejad 1,*, Fariba Afroozan 1, Bita Bozorgmehr 1, Alireza Ghanadan 2,3, Susan Akbaroghli 4, Hamid Reza Khorram Khorshid 5, Faezeh Mojahedi 6, Aria Setoodeh 7, Abigail Loh 8, Yu Xuan Tan 8, Nathalie Escande-Beillard 8, Fransiska Malfait 9, Bruno Reversade 8, Thatjana Gardeitchik 10 and Eva Morava 10,11 1 Kariminejad-Najmabadi Pathology & Genetics Center, #2, 4th Street, Hasan Seyf Street, Sanat Square, Tehran 14667-13713, Iran; [email protected] (F.A.); [email protected] (B.B.) 2 Department of Dermatopathology, Razi Dermatology Hospital, Tehran University of Medical Sciences, Tehran 14167-53955, Iran; [email protected] 3 Department of Pathology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran 14197-33141, Iran 4 Clinical Genetics Division, Mofid Children’s Hospital, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran 15514-15468, Iran; [email protected] 5 Genetic Research Centre, University of Social Welfare and Rehabilitation Sciences, Tehran 19857-13834, Iran; [email protected] 6 Mashhad Medical Genetic Counseling Center, Social Welfare and Rehabilitation Organization, Mashhad 91767-61999, Iran; [email protected] 7 Division of Pediatric Endocrinology and Inherited Metabolic Disorders, Department of Pediatrics, Tehran University of Medical Sciences, Tehran
    [Show full text]
  • Download CGT Exome V2.0
    CGT Exome version 2.
    [Show full text]
  • Genes Covered and Disorders Detected by X-HR Microarray
    UPMC Cytogenetics Laboratory X High Resolution Microarray GENES COVERED BY X-HR AND SYNDROMES DETECTED BY X-HR Gene Location Syndrome ABCB7 Xq12-q13 Anemia, sideroblastic, with ataxia ABCD1 Xq28 Adrenoleukodystrophy ACSL4 Xq22.3-q23 X-linked mental retardation AFF2 Xq28 Fragile X E (FRAXE) mental retardation AGTR2 Xq22-q23 Mental retardation, X-linked ALAS2 Xp11.21 Anemia, sideroblastic, X-linked AP1S2 Xp22.2 Mental retardation, X-linked AR Xq11.2-q12 Androgen insensitivity syndrome ARHGEF6 Xq26.3 Mental retardation, X-linked ARHGEF9 Xq11.1 X-linked mental retardation (XLMR)//Hyperekplexia and epilepsy ARSE Xp22.3 Chondrodysplasia punctata, X-linked recessive (CDPX) ARX Xp21 Infantile spasm syndrome, X-linked (ISSX), West, Proud, XLAG, Partington, multifocal epilepsy //Early infantile epileptic encephalopathy-1 (EIEE1)( X-linked infantile spasm syndrome-1-ISSX1) ATP6AP2 Xp11.4 Mental retardation, X-linked, with epilepsy (XMRE) ATP7A Xq13.2- Menkes disease (MNK) and occipital horn syndrome q13.3 ATRX Xq13.1- ATRX, XLMR-Hypotonic facies syndrome, ATR-X, and others q21.1 AVPR2 Xq28 Nephrogenic syndrome of inappropriate antidiuresis; NSI; Diabetes insipidus, nephrogenic BCOR Xp21.2- Microphthalmia syndromic (MCOPS2) p11.4 BMP15 Xp11.2 Ovarian dysgenesis 2 BRWD3 Xq21.1 Mental retardation, X-linked 93 BTK Xq21.33-q22 X-linked agammaglobulinemia CACNA1F Xp11.23 Aland Island eye disease CASK Xp11.4 X-linked mental retardation with microcephaly & disproportionate pontine and cerebellar hypoplasia (MICPCH) syndrome CD40LG Xq26 Immunodeficiency,
    [Show full text]